REATA

OVERVIEW

PIPELINE

MANAGEMENT TEAM

SCIENTIFIC ADVISORS

BOARD OF DIRECTORS

Reata has built a highly collaborative and effective team of pharmaceutical industry veterans

Management Team

	Warren Huff, Founding Chief Executive Officer and President Mr. Huff was the Chief Executive Officer of Ergo Science Corporation, a biopharmaceutical company based in Boston, Massachusetts that developed neurotransmitter-modulating drugs for the treatment of type II diabetes and obesity. Mr. Huff joined Ergo as its first business executive and, under his leadership, Ergo progressed from seed capital to initial public offering in 39 months. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University.

	Elaine Castellanos, Director of Financial Reporting and Controller Ms. Castellanos joined Reata in 2008. She was previously a Senior Manager with the health sciences group at Ernst & Young, bringing over 12 years of financial reporting and public accounting experience. Her clients ranged from non-profits and development stage companies to the Fortune 500. Ms. Castellanos received a B.A. degree in Economics and Managerial Studies and a Masters of Accounting from Rice University. She is also a Certified Public Accountant.

	Casi DeYoung, Vice President of Business Development Ms. DeYoung brings 13+ years of experience in the pharmaceuticals business. Her roles have included business development, portfolio and project management, commercial operations and management consulting in biotech firms as well as mid-size and large pharmaceutical companies in the US and abroad. Most recently, she served as Vice President, Business Development for ODC Therapy with responsibilities for licensing, alliance management and commercialization planning. Prior to ODC, she held US and global positions at EMD Pharmaceuticals, the U.S. subsidiary of Germany-based Merck KGaA. Ms. DeYoung began her career in the pharmaceuticals business with Accenture. She received a B.S. degree in Chemistry and Mathematics from Southwestern University and an MBA from the University of Texas.

	Deborah Ferguson, Ph.D. Director of Discovery Research Dr. Ferguson was instrumental in developing and implementing one of Reata’s original founding technologies. Insights from Dr. Ferguson drove the discovery of the mechanism of action of the AIM class of compounds. Dr. Ferguson received a B.Sc. in Genetics from the University of Manitoba graduating with First Class Honours and holds a Ph.D. in Experimental Medicine from McGill University. Dr. Ferguson completed her post-doctoral training at the UT Southwestern Medical Center at Dallas.

	Eric Grossman, M.D. Vice President of Clinical Development and Medical Affairs Dr. Grossman is responsible for design and implementation of drug development strategies for all phases of drug development. His previous experience includes Vice President at Keryx Pharmaceuticals (clinical development/medical affairs), Medical Director at the New York Organ Donor Network, and Group Leader/Senior Medical Director at Pfizer Inc.. Dr. Grossman received a B.A. in biology from University of Chicago and his M.D. from Pritzker School of Medicine, University of Chicago. He completed his internship and residency at the Tufts-New England Medical Center in Boston, MA and a fellowship in Nephrology at the Brigham and Women’s Hospital in Boston, MA. He has held faculty appointments at Harvard Medical School, the University of Rochester and NYU Medical School.

	Betty Holland, Senior Director of Regulatory Affairs and Quality Assurance Ms. Holland brings 25+ years of drug development experience to Reata, including more than 18 years of regulatory experience with pharmaceutical and biotechnology products. Before joining Reata, she was President of BCH Regs, Inc., a regulatory consulting firm. Previously, she was Senior Director of Regulatory Affairs at Tanox, Inc., where she also served as the Tanox project leader on a three-company global development team. The majority of her career was with Hoffmann-La Roche, Inc. where her roles included regulatory affairs, project management, and scientific writing. She was involved in both development and post-approval activities, and has experience with IND filings, NDA and SNDA submissions and approvals, FDA Advisory Committee Meetings, and risk management systems. Ms. Holland received an M.S. in organic chemistry from Purdue University and a B.S. in chemistry from Iowa State University.

	Robin Kral, Vice President of Licensing and Intellectual Property Mr. Kral joined Reata from the University of Texas Southwestern Medical Center at Dallas (UT Southwestern), where he was Associate Director for Venture Development. At UT Southwestern, he played a leading role in assembling Reatas project portfolio and developing its business plan. Before joining UT Southwestern, Mr. Kral was in positions of increasing responsibility in research, market and competitive analysis, product development and business development at NPS Pharmaceuticals in Salt Lake City. His last position at NPS was as Director of Business Development. Mr. Kral has B.S. and M.S. degrees in biology from Texas Tech University, and received his M.B.A. from the David Eccles School of Business at the University of Utah.

	Melissa Krauth, Vice President of Strategy and Analytics Leveraging her 15+years of pharmaceutical industry experience, Ms. Krauth provides strategic and operational support to ensure projects remain on track to deliver maximum commercial value. Prior to joining Reata, Ms. Krauth was President and co-founder of DrugVoice LLC, a market research and consulting company serving leading pharmaceutical companies. Additionally, she has many years of experience with a leading strategy consulting firm, concentrating on pharmaceutical project/portfolio management and commercialization. Ms. Krauth holds an M.B.A. degree in Strategic Management and Health Care Management from The Wharton School of the University of Pennsylvania and is a cum laude graduate of Rice University with a degree in Biochemistry.

	Colin Meyer, M.D. Vice President of Product Development Dr. Meyer's primary role is to develop and implement strategies to move product candidates expeditiously through all stages of development. His duties include overseeing all preclinical development, determining relevant primary and surrogate endpoints for clinical studies, and developing clinical strategies for the drug candidates. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

	Barbara Richardson, Senior Director of Clinical Operations Ms. Richardson has over 20 years of clinical research experience in the site, CRO and sponsor environments. She has held clinical, training and regulatory positions during the previous 10 years at MedTrials, Inc. where she most recently held the positions of Vice President, Compliance and Regulatory Affairs and Vice President, Clinical and Regulatory. She is a Registered Nurse in the State of Texas, and has served as Adjunct Faculty for the University of North Texas Health Science Center, Adjunct Clinical Instructor for The University of Texas at Arlington, and as Faculty Associate for The University of Texas Southwestern Medical Center at Dallas. Barbara received a BSN and MSN from the University of Texas at Arlington and is Regulatory Affairs Certified (RAC) through the Regulatory Affairs Professionals Society (RAPS).

	Mike Visnick, Ph.D. Vice President of Medicinal Chemistry Dr. Visnick brings to the management team over 23 years of experience in preclinical research while with Hoffmann LaRoche, Parke-Davis and Pfizer. Dr. Visnick has managed research groups in the inflammatory, metabolic and CNS disease areas, as well as directed the computational sciences group at Pfizer. He received his Ph.D. in organic chemistry from the University of Florida, and spent 2 years as an American Cancer Society Postdoctoral Fellow at the University of Pennsylvania. He has been a member of the American Chemical Society for over 25 years and is currently an Adjunct Professor of Chemistry at the University of Michigan College of Pharmacy.

	John Walling, Ph.D. Vice President of Manufacturing Operations Dr. Walling brings over 20 years of pharmaceutical development experience to the Reata organization. Dr. Walling joined Reata after making significant contributions at Ferro Pfanstiehl Laboratories where he was Director of Chemical and Process Technology. He was instrumental in assisting the company in establishing a successful Fee for Service business strategy and platform focusing on development and commercial manufacturing of cytotoxic and highly potent active pharmaceutical ingredients. Previously, Dr. Walling held positions of increasing responsibility in research, development and manufacturing operations within ILEX Oncology, Cambrex Corporation and Abbott Laboratories. Dr. Walling has a Ph.D. in Organic Chemistry from Iowa State University with a focus on natural products synthetic chemistry. He also holds a RAC certification from the Regulatory Affairs Professionals Society.

	W. Christian Wigley, Ph.D. Vice President of Research and Founding Scientist Dr. Wigley is co-inventor of Reata's pioneering protein folding technology platform and is recognized as a leader in the field of protein misfolding and disease. Prior to joining Reata, Dr. Wigley was a Senior Research Scientist in the Department of Physiology, UT Southwestern Medical Center, where he championed the design and development of assays to monitor protein misfolding associated with a variety of pathologies. Dr. Wigley received a B.S. in Biochemistry and a Ph.D. in Chemistry from Texas Tech University. His post-doctoral training was conducted in the Departments of Molecular Genetics and Physiology at UT Southwestern.

	Jason Wilson, Vice President of Finance Mr. Wilson joined Reata in 2006 and has over 14 years financial management and accounting experience in life sciences-related businesses. From 2003 until 2006 he served as Vice President, Finance & Corporate Controller at Caris Diagnostics, a specialty laboratory company. Previously, he was a Senior Manager in the health-sciences group at Ernst & Young's Dallas office serving clients across the healthcare spectrum from the start-up to IPO phase, to the Fortune 1000. Mr. Wilson holds a BBA in Accounting, an MBA and is a Certified Public Accountant.